Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Why Shares of Cassava Sciences Soared This Week
03:13pm, Friday, 06'th Oct 2023
A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzheimer's disease drug.
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
09:15am, Thursday, 05'th Oct 2023
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that Remi Ba
The 7 Best Meme Stocks to Buy Now: September 2023
06:30am, Thursday, 14'th Sep 2023
Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. I
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
09:15am, Wednesday, 06'th Sep 2023
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that it has
Week Of 08/28 Notable Insider Buys
11:46pm, Tuesday, 05'th Sep 2023
Energy Transfer LP, Cassava Sciences, and PENN Entertainment Inc. were discussed in last week's insider trades update. CEO of Sirius XM Holdings Inc., Jennifer Witz, purchased 250,000 shares for over
Week Of 08/21 Notable Insider Buys
03:15pm, Tuesday, 29'th Aug 2023
Energy Transfer LP CEO and Executive Vice President make significant insider purchases, with the CEO's YTD purchases totaling around $115 million. Cassava Sciences directors purchase shares amidst dis
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
09:31am, Thursday, 24'th Aug 2023
Cassava Sciences (NASDAQ: SAVA ) stock jumped 5% overnight after director Richard Barry revealed he acquired shares on behalf of his trust. Barry paid $16.80 for each of the 1,905 shares on Aug. 21.
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
07:31am, Thursday, 13'th Jul 2023
The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the s
Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials
10:48am, Sunday, 09'th Jul 2023
Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials
Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results
03:38pm, Wednesday, 05'th Jul 2023
Cassava Sciences (NASDAQ: SAVA ) stock is well in the red today despite announcing Phase 3 results for its Alzheimer's treatment. Indeed, SAVA stock is down more than 10% at the time of this writing o
Cassava Sciences: Why Market Skepticism Persists Despite Positive Findings On Simufilam
03:05pm, Wednesday, 05'th Jul 2023
Cassava Sciences' Alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but the results were not statistically significant, raising doubts about its efficacy. Despite a cash
Why Shares of Cassava Sciences Are Dropping Wednesday
11:44am, Wednesday, 05'th Jul 2023
Simufilam slowed cognitive decline by 38% compared to a placebo after six months for patients with mild to moderate Alzheimer's disease. Cassava Sciences has been the target of shareholder lawsuits, s
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
09:15am, Thursday, 01'st Jun 2023
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that its management has b
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
01:11pm, Tuesday, 30'th May 2023
Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
Why Shares of Cassava Sciences Jumped This Week
04:39pm, Friday, 12'th May 2023
The company has a small pipeline. Cassava also released data showing that Simufilam could be useful as an oncology drug.
